Status:
COMPLETED
Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. O...
Eligibility Criteria
Inclusion
- Ocular hypertension or glaucoma in both eyes
- Require IOP-lowering therapy in each eye
Exclusion
- Uncontrolled systemic disease
- Known allergy or hypersensitivity to bimatoprost
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT00652496
Start Date
January 1 2005
End Date
May 1 2005
Last Update
April 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wenatchee, Washington, United States